Clovis Oncology, Inc. (CLVS) Q2 2021 Earnings Conference Call August 4, 2021 8:30 AM ET
Company Participants
Anna Sussman - IR
Patrick Mahaffy - CEO
Thomas Harding - Chief Scientific Officer
Lindsey Rolfe - Chief Medical Officer
Dan Muehl - CFO
Conference Call Participants
Gavin Scott - JPMorgan
Tazeen Ahmad - Bank of America
Paul Choi - Goldman Sachs
Andrew Berens - SVB Leerink
Joe Catanzaro - Piper Sandler
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Clovis Oncology Q2 2021 Operating Results Webcast Conference call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions]
I would now like to hand the conference over to your speaker, Anna Sussman, Vice President of Investor Relations. Thank you. Please go ahead.
Anna Sussman
Thank you, Bella. Good morning, everyone. Welcome to the Clovis Oncology Second Quarter 2021 Conference Call. Thanks for joining us. You've likely seen this morning's press release, and if not, it's available on our website at clovisoncology.com. As a reminder, this conference call is being recorded and webcast. Remarks may be accessed live on our website during the call and will be available on our archive for the next several weeks.
Today's agenda includes the following, Patrick Mahaffy, our President and CEO, will discuss the highlights of today's corporate update; and then Dr. Thomas Harding, our Chief Scientific Officer, will present an update on our FAP-2286 and targeted radionuclide therapy development programs; Dr. Lindsey Rolfe, our Chief Medical Officer, will discuss the anticipated upcoming clinical milestones for Rubraca and F2286; then Dan Muehl, our Chief Financial Officer, will cover this quarter's results in greater detail. Patrick will make a few brief remarks -- sorry, a few brief -- a brief review of corporate strategy and make a few closing remarks. And then we'll open the call for Q&A, during which John, Pat and Tom and Linde will be available for questions.
- Read more current CLVSQ analysis and news
- View all earnings call transcripts